Logo

FDA Approves First Targeted Therapy for Metastatic Bladder Cancer

ARTICLES

FDA Approves First Targeted Therapy for Metastatic Bladder Cancer


PRACTICE UPDATE

PUBLISHED: 15 APRIL 2019


The U.S. Food and Drug Administration today granted accelerated approval to Balversa (erdafitinib), a treatment for adult patients with locally advanced or metastatic bladder cancer that has a type of susceptible genetic alteration known as FGFR3 or FGFR2, and that has progressed during or following prior platinum-containing chemotherapy.

explore_now-footer.png

Published

April 15, 2019

Categories

Oncology
CP-202103